Active Ingredient(s): Atogepant
FDA Approved: * September 28, 2021
Pharm Company: * ABBVIE INC
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Qulipta Overview

Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.[1][2] It was approved for medical use in the United States in September 2021.[1][3] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0...

Read more Qulipta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Atogepant

Recent Qulipta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 10mg, 30mg, 60mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Qulipta: (3 results)

Sorted by National Drug Code
  • 0074-7094 Qulipta 60 mg Oral Tablet by Abbvie Inc.
  • 0074-7095 Qulipta 10 mg Oral Tablet by Abbvie Inc.
  • 0074-7096 Qulipta 30 mg Oral Tablet by Abbvie Inc.

Other drugs which contain Atogepant or a similar ingredient: (1 result)